Tiziana Life Sciences' ALS Trial Joins MyMatch Program
Ticker: TLSA · Form: 6-K · Filed: Nov 25, 2025 · CIK: 1723069
Sentiment: bullish
Topics: clinical-trial, drug-development, neurology, als
TL;DR
Tiziana's ALS drug trial accepted into Sean M. Healey & AMG Center's MyMatch Program.
AI Summary
Tiziana Life Sciences Ltd announced on November 25, 2025, that its Phase 2 clinical trial for intranasal foralumab in ALS patients has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center. This inclusion is a significant step for the company's research into treating amyotrophic lateral sclerosis.
Why It Matters
The inclusion of Tiziana's trial in the ALS MyMatch Program could accelerate patient access to potential new treatments and provide valuable data for the development of foralumab for ALS.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, and the success of foralumab in treating ALS is not yet proven.
Key Players & Entities
- Tiziana Life Sciences Ltd (company) — Registrant
- foralumab (drug) — Investigational drug for ALS
- amyotrophic lateral sclerosis (ALS) (disease) — Condition being studied
- ALS MyMatch Program (program) — Clinical trial matching program
- Sean M. Healey & AMG Center (company) — Center hosting the MyMatch Program
- November 25, 2025 (date) — Date of announcement
FAQ
What is the specific goal of the Phase 2 clinical trial for intranasal foralumab?
The filing does not specify the exact goals of the Phase 2 trial, but it is evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS).
What is the ALS MyMatch Program?
The ALS MyMatch Program is a program at the Sean M. Healey & AMG Center that aims to match ALS patients with relevant clinical trials.
What is the significance of being accepted into the ALS MyMatch Program?
Acceptance into the ALS MyMatch Program signifies that Tiziana's Phase 2 trial meets certain criteria and can potentially enroll patients identified through the program, accelerating recruitment.
What is the primary indication for foralumab being tested?
The primary indication being tested for foralumab in this trial is amyotrophic lateral sclerosis (ALS).
When was this announcement made?
The announcement was made on November 25, 2025.
Filing Stats: 326 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2025-11-25 08:30:01
Filing Documents
- ea0267112-6k_tiziana.htm (6-K) — 22KB
- ea026711201ex99-1_tiziana.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-114407.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: November 25, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Press Release, dated November 25, 2025 3